A 35-year-old man with a history of intravenous drug use presents with a 2-week history of fever, malaise, and new cardiac murmur (holosystolic murmur at the left lower sternal border). Echocardiography reveals a 1.2 cm vegetation on the tricuspid valve with moderate tricuspid regurgitation. Blood cultures (3 sets) grow Gram-positive cocci in clusters, catalase-positive, coagulase-positive, resistant to oxacillin. What is the most appropriate initial antibiotic regimen?

Explanation

## Clinical Diagnosis **Key Point:** Right-sided endocarditis (tricuspid valve involvement) in an IVDU with MRSA bacteremia is a classic presentation. The organism is identified as Gram-positive, catalase-positive, coagulase-positive, and oxacillin-resistant = **MRSA**. ## Organism Confirmation | Test | Result | Interpretation | |------|--------|----------------| | **Gram stain** | Cocci in clusters | Staphylococcus sp. | | **Catalase** | Positive | Not Streptococcus | | **Coagulase** | Positive | S. aureus (not S. epidermidis) | | **Oxacillin resistance** | Resistant | MRSA (mecA gene present) | **High-Yield:** MRSA is the leading cause of infective endocarditis in IVDUs in developed countries and increasingly in India. Right-sided (tricuspid) involvement is typical in IVDU endocarditis. ## Treatment of MRSA Endocarditis **Clinical Pearl:** Vancomycin monotherapy is inadequate for S. aureus endocarditis. Combination therapy with an aminoglycoside is required for synergy and improved bactericidal activity, especially in the setting of prosthetic valves or complex disease. ### Recommended Regimen for Native Valve MRSA Endocarditis 1. **Vancomycin 15–20 mg/kg IV Q8–12H** - Target trough: 15–20 μg/mL (higher targets for CNS involvement) - Renal function monitoring essential 2. **Gentamicin 3 mg/kg IV Q8H** (first 2 weeks minimum) - Provides synergy against S. aureus - Improves valve sterilization and reduces embolic complications - Monitor renal function and peak/trough levels ### Duration - **Native valve:** 4–6 weeks of vancomycin + gentamicin (first 2 weeks) - **Prosthetic valve:** 6 weeks of vancomycin + gentamicin (first 2 weeks), followed by 4 weeks of vancomycin monotherapy **Mnemonic:** **VG-MRSA** = **V**ancomycin + **G**entamicin for **MRSA** endocarditis. ## Why This Answer MRSA endocarditis requires dual therapy for optimal outcomes. Vancomycin penetrates vegetations and provides reliable MRSA coverage; gentamicin adds synergy and improves bacterial killing. This combination is guideline-recommended for both native and prosthetic valve disease.